Active, not recruitingPHASE1, PHASE2NCT03212742

Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

Studying Glial tumor

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Centre Francois Baclesse
Intervention
Olaparib(drug)
Enrollment
91 target
Eligibility
18-70 years · All sexes
Timeline
2017 – 2026

Study locations (15)

Collaborators

National Cancer Institute, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03212742 on ClinicalTrials.gov

Other trials for Glial tumor

Additional recruiting or active studies for the same condition.

See all trials for Glial tumor →

← Back to all trials